Rapha Laboratories, LLC

Rapha Laboratories, LLC was paid $485K by Medicaid between May 2023 and Dec 2024, across 11 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 39% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in North Carolina

Rank by total paid#52 of 128

Median peer was paid$268K

This provider vs. median1.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2023	1,194	$96K
2024incomplete	4,127	$389K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	39%	1,355	954	$188K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	38%	1,681	958	$183K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	17%	1,346	1,026	$82K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	5.3%	625	440	$26K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	70	33	$2K
87563		<1%	44	33	$852.54
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	44	33	$828.77
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	43	32	$798.23
87625		<1%	44	33	$793.53
87529		<1%	39	29	$679.63
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	30	20	$451.16

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBROOKS, JERMAINE (PRESIDENT)